Xiamen tebao bioengineering co., ltd.

200 1, the company invested more than 30 million yuan to set up Bosai Gene Transcription Technology Company. The company has mastered the industrial development ability of the whole process of genetic engineering new drugs-from cloning target genes, gene recombination, construction of engineering bacteria, cell culture and purification to preparations, as well as the organization of pre-clinical trials and clinical research of new drugs and the application of new drugs. The research center has provided a strong impetus for the follow-up development of special insurance.

The company has built a genetic engineering pharmaceutical base covering an area of 37,000 square meters in Xinyang Industrial Zone, Haicang, Xiamen, and passed GMP certification in National Medical Products Administration, China in July 2000. The pharmaceutical base has advanced aseptic production workshop, supporting power workshop and clean animal experiment center. And adopt the most advanced production equipment and scientific research and testing instruments in the world. The production process is strictly in accordance with GMP standards.

Since its establishment, the company has focused on the research and development of cancer treatment and hematological drugs, and devoted itself to the research and development of original new drugs in key areas and the rapid industrialization of scientific and technological achievements. Independent research and development of three national new drugs:

Teli rHuGM-CSF (Topleucon)

Recombinant human granulocyte colony stimulating factor

Telecom rHuIL- 1 1 (Topmega)

Starting from 1997, TPB cooperated with China Institute for the Control of Pharmaceutical and Biological Products, and successively established and completed the preparation of China national homogeneous standards for seven protein drugs, including GM-CSF, G-CSF, IL-1,IFNα-2a, IFNα-2b, IL-2 and GH.

With its strong technical development advantages, the special protection organism is conducting the first and second phase clinical research of Class II new drugs in five countries and the clinical application of Class I new drugs in five countries.